RT-PCR for CCR5 gene FIG. 1A Harris Br. 40 IL-13 IFN- \(\gamma\) (C57B/6) IFIN- y (Balb/c)




FIG. 2A

IFN γ TG Anti-CCR5 MIP-1 α MIP-1 β RANTES








FIG. 2B






SUBSTITUTE SHEET (RULE 26)








WO 2005/058234




SUBSTITUTE SHEET (RULE 26)











SUBSTITUTE SHEET (RULE 26)





Proteinase and anti-proteinase after blocking and null mutation of CCR5 in IFN-y mice




FIG. 8B TUNEL Staining in IFN-y Mouse Lung after **FIG. 8D** blocking and null mutation of CCR5 + IFNy TG CCR5 +/+ CCR5 TUNEL (+) Cells (%) Ctrl IgG Anti-CCR5 FIG. 8A IFNY TG FIG. 8C






FIG. 8E 10⁰ 10¹ 10² 10³ 10⁴ FL-2-An **QUAD EVENTS % GAINED TOTAL** 0.00 0.00 **UR** 202 2.15 2.02 LL LR 0666 95.08 60.65 109 2.14 1.99

FIG. 8F



<u>QUAD</u>	EVENTS	% GAINED	% TOTAL
UL	0	0.00	0.00
UR	540	25.59	5.45
LL	923	45.97	9.23
LR	545	27.14	5.45

FIG. 8G



QUAD	EVENTS	% GAINED	% TOTAL
UL	7	0.12	0.07
UR	541	9.47	5.41
LL	41.96	73.45	41.98
LR	960	18.96	9.69

FIG. 9A




FIG. 9D




FIG. 9B





FIG. 9E








FIG. 9F

150
125100(m/nould)
75250IFN-y - + +
CCR5 +/+ -/- +/+ -/-

FIG. 9G







SUBSTITUTE SHEET (RULE 26)

10x H&E FIG. 10B HISTOLOGY (HE) AFTER TWO MONTHS SMOKING EXPOSURE SMOKING EXPOSURE NON-SMOKING EXPOSURE CCR5 +/+


SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)










FIG. 13


Lung Volume of IL-13 Mice After block and null mutation of CCR5











SUBSTITUTE SHEET (RULE 26)





FIG. 15

			() () () () () () () () () ()	12		The state of the s		X		S-	The second sections of the section sections of the second section sections of the second section sections of the section section sections of the section sec	6. 14 1. 14 1. 14 1. 14 1. 14 1. 14 1. 14 1. 14 1. 14 1. 14 1. 14 1. 14 1. 14 1. 14 1. 14 1. 14 1. 14 1. 14 1.	-3	7.	in		
9	IL-13 TG	CCKS MMP-2	MMP-9	MMP-12	MMP-14	Cath-B	Cath-H	Cath-K	Cath-L	Cath-S	CI-AT	TIMP-1	TIMP-3	TIMP-4	Bactin		
	+ +	-	imme Salve Fredskild		Control of the second second				The second secon		the practice eventual between the contract of	the sector than the second	The second second		The second second	REAL STREET, S	
	IL-13TG AntiCCR5	MMP-2	MMP-9	MMP-12	MMP-14	Cathe B	Cathe H	Cathe K	Cathe L	Cathe S	α1-AT	TIMP-1	TIMP-2	TIMP-4	SLPI	Cystatin C	ß-actin

SUBSTITUTE SHEET (RULE 26)

BAL IL-13 Level of iIL-13 mice treated with Anti-CCR5 antibody FIG. 17



-13 Mouse Lung






FIG. 19


+ _		A Company of Company o				(^{g)*} 奇智) to th			(2)		
+ +						हिंदारे १ भेन्ते विकासादाद्यां	gan il man	14			
						-		igi igi	, 13	(1925年,宋代1925年) 《新山北小台》,张达里的	(1)
- +						H		· · · · · · · · · · · · · · · · · · ·	,		
IL-13 TG CCR5	FasL	Fas	$ extsf{TNF-}\alpha$	TNFR-1	TNFR-2	Caspase-3	Caspase-8	Caspase-9	Bid	Bax	Bactin
+ +		- constant the state of the sta		President Colonial to the second of a figure of the second		Transfer Colors				THE CASE SECTION AND PROPERTY.	
IL-13TG AntiCCR5	FasL	Fas	TNF- α	INFR-1	INFR-2	Caspase-3	Caspase-8	Caspase-9	Bid	Вах	Bactin

Western Blot Detecting Apoptotic Factors in IL-13 Transgenic Mouse Lungs FIG. 20





SUBSTITUTE SHEET (RULE 26)



Caspase Activities of CCR5ko/IL-1





FIG. 24 CD4+ Cells in CC10-IFN- γ Mouse Lung



FNgtg-12704.014 iIFNy tg CD3 iIFNy tg H-174 $\overline{\text{CD3}}$ CD3

37/38

NK Cells in CC10-IFN-γMouse Lung

WT NK cells

104 | FNgq-12704.018

105 | 104 | FNgq-12704.018

106 | 107 | 108 | 104 | FNgq-12704.020

106 | 107 | 108 | 108 | 104 | FNgq-12704.020

107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107 | 107